Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Oct 7;17(10):e0265792. doi: 10.1371/journal.pone.0265792

Risks for death after admission to pediatric intensive care (PICU)—A comparison with the general population

Tova Hannegård Hamrin 1,2,*, Staffan Eksborg 1,3
Editor: Robert Jeenchen Chen4
PMCID: PMC9543762  PMID: 36206205

Abstract

Objective/aim

The aim of the study was to quantify excess mortality in children after admission to a Pediatric Intensive Care Unit (PICU), compared to the age and sex matched general Swedish population.

Design

Single-center, retrospective cohort study.

Setting

Registry study of hospital registers, a national population register and Statistics Sweden.

Patients

Children admitted to a tertiary PICU in Sweden in 2008–2016.

Interventions

None.

Main results

In total, 6,487 admissions (4,682 patients) were included in the study. During the study period 444 patients died. Median follow-up time for the entire PICU cohort was 7.2 years (IQR 5.0–9.9 years). Patients were divided into four different age groups (0–28 d, > 28 d -1 yr, > 1–4 yr, and > 4 yr) and four different risk stratification groups [Predicted Death Rate (PDR) intervals: 0–10%, > 10–25%, > 25–50%, and > 50%] at admission. Readmission was seen in 929 (19.8%) patients. The Standardized Mortality Ratios (SMRs) were calculated using the matched Swedish population as a reference group. The SMR for the entire study group was 49.8 (95% CI: 44.8–55.4). For patients with repeated PICU admissions SMR was 108.0 (95% CI: 91.9–126.9), and after four years 33.9 (95% CI: 23.9–48.0). Patients with a single admission had a SMR of 35.2 (95% CI: 30.5–40.6), and after four years 11.0 (95% CI: 7.0–17.6). The highest SMRs were seen in readmitted children with oncology/hematology (SMR = 358) and neurologic (SMR = 192) diagnosis. Children aged >1–4 years showed the highest SMR (325). In PDR group 0–10% children with repeated PICU admissions (n = 798), had a SMR of 100.

Conclusion

Compared to the matched Swedish population, SMRs were greatly elevated up to four years after PICU admission, declining from over 100 to 33 for patients with repeated PICU admissions, and from 35 to 11 for patients with a single PICU admission.

Introduction

Mortality rates in pediatric intensive care units (PICU) have decreased significantly during the last decades [13]. The reasons are multifactorial: centralization of intensive care for children to tertiary PICUs, medical and technological advances, dedicated pediatric inter-hospital transport teams, and specialized training in pediatric intensive care are some [48]. Children who would previously have died, survive because of these improvements in intensive care. There is also a growing number of PICU patients who would not have been admitted previously due to preexisting complex chronic illnesses [5, 6]. It has been hypothesized that improving intensive care survival and expanded indications for intensive care despite complex chronic disease, contribute to increasing post-PICU mortality. Thus, assessing PICU mortality alone might not reflect the true severity of pediatric critical illness. In a previous study we found that critically ill children in need of transport to a tertiary PICU showed a continued mortality risk after PICU discharge [9].

Studies on outcomes after pediatric intensive care have assessed mortality and morbidity from a wide range of different aspects: certain ICU-diagnoses and patient groups, admission to ICU vs PICU, different follow-up time, etc. [1, 2, 1016]. Only two studies have compared outcome to a non-ICU, age-matched control population; a Swedish study comparing children treated in PICU and general ICU 1998–2001 and a Finnish study investigating children admitted to PICU or general ICU 2009–2010 [17, 18]. In these two studies, data on the severity of illness at admission was lacking, hence there was no adjustment for the case mix. The aim of the present study was to quantify excess mortality after single and repeated admissions to a PICU, compared with an age and sex matched control group from the general Swedish population over time. The study group was characterized by age, sex, severity of illness and PICU admission diagnosis.

Materials and methods

Setting

This study was conducted at the PICU at the Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden. This tertiary referral center for critically ill children has roughly 750 annual admissions and provides intensive care to medical and surgical patients, including neurosurgery, thoracic surgery, and extracorporeal membrane oxygenation (ECMO) therapy but not cardiac surgery. Non-elective admissions make up approximately 80% of the total admissions to the PICU.

Data source

The study was conducted as a single-center, retrospective study of prospectively collected data. It was approved by the Swedish Ethical Review Authority (DNr 2013/1078-31/2, 2016/1789-32 and 2020–05528) and registered in the Australian New Zealand Clinical Trials Registry with registration number ACTRN12621001303831. The data contained no protected health information, and there were no changes in patient care due to database entry, thus the need for informed patient consent was waived. Data were collected from consecutive admissions to the PICU from January 1, 2008, to December 31, 2016. The study population consisted of neonatal patients aged from >36 gestational weeks to adolescents aged 18 years. Patients admitted to the PICU are registered in a Patient Data Management System (PDMS; Centricity Critical Care; GE Healthcare Sverige AB, Danderyd, Sweden). The Pediatric Index of Mortality (PIM) score and its different variables are documented in the database. PIM is a widely used model to predict intensive care mortality (predicted death rates [PDRs]) for children by using admission data [19, 20]. The latest version of the PIM score (PIM-3) was adopted in Sweden at the end of 2016; thus, only PIM-2 was used in the present study.

Data collection and patients

All data from the PDMS were received in electronic form and transformed into a Microsoft Excel 2010 spreadsheet (Microsoft, Redmond, WA). All entered data were manually and electronically checked for errors, that is, extreme or obviously conflicting data. The subjects were divided into four different age groups (0–28 d, > 28 d–1 yr, > 1–4 yr, and > 4 yr) and four different risk stratification groups (PDR intervals: 0–10%, > 10–25%, >25–50%, and > 50%) at admissions. All admissions were investigated regarding background data, PICU admission diagnosis (International Classification of Diseases, 10th Edition, Swedish Edition), and PICU length of stay (PICU-LOS). Mortality included discontinuation of treatment. PICU mortality was gathered from the PDMS for all patients. Data on survival status after PICU discharge were obtained from the population register (Swedish Tax Agency), a separate national database, in which the Swedish population is registered with a unique personal identification number that follows each Swedish citizen from birth to death. The control population consisted of all Swedish individuals of the same age and sex. Statistics Sweden (Statistiska Centralbyrån, Statistikmyndigheten SCB; www.scb.se) provided the mortality data regarding the children in the control group.

A complete dataset on the entire study cohort is available as supplementary material (S1 Table).

Statistical analysis

Data are reported as n (%) and median values (IQR) unless otherwise stated, where n is the number of observations and IQR is interquartile range (IQR). Survival was evaluated by Kaplan-Meier curves. Statistics were evaluated by MS Excel (Microsoft, Redmond, WA) and GraphPad Prism version 5.04 (Graph Pad Software, San Diego, CA). Significance was defined as p< 0.05. Reported p values are from two-sided tests.

Estimation of standardized mortality ratio (SMR)

The SMRs were calculated using the age and sex matched Swedish population as a reference group. For each patient we used the age at admission and follow-up time, or time to death, in weeks. Tables with death rates from the Swedish general population classified by age and sex were received from Statistics Sweden [21]. SMR with 95% confidence intervals was calculated from observed mortality of the PICU population with matched median values of death/week per 1,000 controls from the period 2008–2016 in the general population.

The observed mortality compared to the reference population, expressed as SMR, was evaluated according to the principles given in [2224].

SMR was evaluated for age and risk stratification groups and presented in funnel plots.

Results

In total, 6,671 admissions were registered in the PICU during the period 2008–2016. We excluded 184 admissions: 124 due to the lack of a personal Swedish identification number, 25 due to a protected identity and 53 because of missing PDR information at admission. Survival status was traced in all 6487 remaining admissions (4,682 individual patients; 2,699 males (57.6%)). Readmission to the PICU were seen in 929 patients (19.8%). Of readmitted patients, 556 patients (59.8%) had two PICU admissions. The study participants are depicted in a Consort flow diagram, Fig 1. The hierarchical nature of patients with repeated admissions to PICU is presented as supplementary material (S2 Table).

Fig 1. Consort diagram.

Fig 1

The cohort of patients included in the study, derived from all admissions to the PICU, and presented as single and repeated admissions.

Patient characteristics and diagnostic groups based on the reason for admission to PICU, by age groups for single and repeated admissions, are presented in Tables 1 and 2 (first admission) and Table 3 (last admission), respectively.

Table 1. Patient characteristics and PICU admission diagnosis by age groups: Patients with a single admission.

Age group
0–28 days >28 days—1 year > 1–4 years > 4 years All patients
Number of patients, n (%) 771 (20.50) 945 (25.20) 728 (19.40) 1309 (34.90) 3753
Number of boys, n (%) 458 (59.40) 585 (61.90) 418 (57.40) 714 (54.50) 2175 (58.00)
Age, median (IQR) 5.75 days 96.90 days 1.95 years 10.70 years 1.35 years
(1.40–15.50) (55.00–197.40) (1.39–2.79) (6.94–14.00) (0.12–7.39)
PDR, median (IQR) 2.08 1.18 1.31 1.05 1.30
(1.02–6.30) (0.58–3.88) (0.75–4.26) (0.75–3.16) (0.75–3.89)
Care time days, median (IQR) 2.40 1.17 0.86 0.81 1.00
(0.97–4.84) (0.76–2.99) (0.54–1.92) (0.52–1.53) (0.64–2.75)
Diagnostic groups, n (%)
Nephrology 8 (1.04) 10 (1.06) 6 (0.82) 15 (1.15) 39 (1.04)
Certain perinatal conditions 94 (12.20) 40 (4.23) 2 (0.27) 0 (0) 136 (3.62)
Gastrointestinal including hepatic failure 41 (5.32) 41 (4.34) 25 (3.43) 39 (2.98) 146 (3.89)
Infection including septic shock + systemic inflammatory response syndrome 43 (5.58) 54 (5.71) 48 (6.59) 62 (4.74) 207 (5.52)
Haematology and oncology 12 (1.56) 27 (2.86) 67 (9.20) 94 (7.18) 200 (5.33)
Cardiovascular/Circulatory 53 (6.87) 51 (5.40) 28 (3.85) 86 (6.57) 218 (5.81)
Endocrine and metabolic diseases 14 (1.82) 44 (4.66) 50 (6.87) 195 (14.90) 303 (8.07)
Trauma and poison 6 (0.78) 41 (4.34) 113 (15.50) 368 (28.10) 528 (14.10)
Observations, postoperative or symptom based 28 (3.63) 116 (12.30) 45 (6.18) 162 (12.40) 351 (9.35)
Neurological including convulsions 15 (1.95) 67 (7.09) 120 (16.50) 144 (11.00) 346 (9.22)
Malformations 288 (37.40) 118 (12.50) 22 (3.02) 29 (2.22) 457 (12.20)
Respiratory 165 (21.40) 336 (35.60) 202 (27.80) 113 (8.63) 816 (21.70)
Unknown 4 (0.52) 0 (0) 0 (0) 2 (0.15) 6 (0.16)

IQR = inter quartile range. Diagnostic groups based on the reason for PICU admission.

Table 2. Patient characteristics and PICU admission diagnosis by age groups: Patients with repeated admissions: First admission.

Age group
0–28 days >28 days—1 year > 1–4 years > 4 years All patients
Number of patients, n (%) 229 (24.70) 312 (33.60) 152 (16.40) 236 (25.40) 929
Number of boys, n (%) 131 (57.20) 189 (60.60) 97 (63.80) 107 (45.30) 524 (56.40)
Age, median (IQR) 1.76 days 113 days 1.88 years 9.56 years 0.50 years
(0.68–10.80) (68.20–180.00) (1.36–2.64) (6.47–13.10) (0.08–4.14)
PDR, median (IQR) 2.27 1.59 1.28 1.14 1.55
(0.92–6.57) (0.75–4.71) (0.75–4.92) (0.75–4.04) (0.75–4.91)
Care time days, median (IQR) 1.98 1.76 1.02 0.92 1.28
(0.79–6.94) (0.85–4.59) (0.60–2.15) (0.61–2.58) (0.73–4.18)
Diagnostic groups, n (%)
Nephrology 3 (1.31) 7 (2.24) 3 (1.97) 1 (0.42) 14 (1.51)
Certain perinatal conditions 8 (3.49) 15 (4.81) 1 (0.66) 1 (0.42) 25 (2.69)
Gastrointestinal including hepatic failure 14 (6.11) 15 (4.81) 6 (3.95) 11 (4.66) 46 (4.95)
Infection including septic shock + systemic inflammatory response syndrome 8 (3.49) 16 (5.13) 8 (5.26) 9 (3.81) 41 (4.41)
Haematology and oncology 4 (1.75) 15 (4.81) 15 (9.87) 22 (9.32) 56 (6.03)
Cardiovascular/Circulatory 15 (6.55) 22 (7.05) 5 (3.29) 21 (8.90) 63 (6.78)
Endocrine and metabolic diseases 7 (3.06) 13 (4.17) 5 (3.29) 14 (5.93) 39 (4.20)
Trauma and poison 0 (0) 5 (1.60) 6 (3.95) 22 (9.32) 33 (3.55)
Observations, postoperative or symptom based 8 (3.49) 25 (8.01) 17 (11.20) 34 (14.40) 84 (9.04)
Neurological including convulsions 3 (1.31) 37 (11.90) 29 (19.10) 55 (23.30) 124 (13.30)
Malformations 126 (55.00) 40 (12.80) 6 (3.95) 5 (2.12) 177 (19.10)
Respiratory 32 (14.00) 102 (32.70) 51 (35.60) 41 (17.40) 226 (24.30)
Unknown 1 (0.44) 0 (0) 0 (0) 0 (0) 1 (0.11)

IQR = inter quartile range, Diagnostic groups based on the reason for PICU admission.

Table 3. Patient characteristics and PICU admission diagnosis by age groups: Patients with repeated admissions: Last admission.

Age group
0–28 days >28 days—1 year > 1–4 years > 4 years All patients
Number of patients, n (%) 75 (8.10) 313 (33.70) 222 (23.90) 319 (34.30) 929
Number of boys, n (%) 40 (53.30) 197 (62.90) 126 (56.80) 161 (50.50) 524 (56.40)
Age, median (IQR) 13.70 days 126.60 days 2.07 years 9.19 years 1.66 years
(5.98–18.40) (66.80–209.00) (1.50–2.83) (6.09–13.40) (0.35–6.30)
PDR, median (IQR) 1.46 1.30 1.17 1.07 1.17
(0.75–3.81) (0.71–3.91) (0.59–3.64) (0.75–3.88) (0.75–3.88)
Care time days, median (IQR) 1.76 1.67 1.01 1.10 1.26
(0.90–3.79) (0.85–4.26) (0.64–3.22) (0.61–3.18) (0.76–3.65)
Diagnostic groups, n (%)
Nephrology 1 (1.33) 5 (1.60) 7 (3.15) 4 (1.25) 17 (1.83)
Certain perinatal conditions 3 (4.00) 13 (4.15) 1 (0.45) 1 (0.31) 18 (1.94)
Gastrointestinal including hepatic failure 7 (9.33) 26 (8.31) 6 (2.70) 15 (4.70) 54 (5.81)
Infection including septic shock + systemic inflammatory response syndrome 1 (1.33) 12 (3.83) 16 (7.21) 11 (3.45) 40 (4.31)
Haematology and oncology 1 (1.33) 14 (4.47) 17 (7.66) 24 (7.52) 56 (6.03)
Cardiovascular/Circulatory 4 (5.33) 19 (6.07) 11 (4.95) 23 (7.21) 57 (6.14)
Endocrine and metabolic diseases 2 (2.67) 13 (4.15) 8 (3.60) 20 (6.27) 43 (4.63)
Trauma and poison 1 (1.33) 4 (1.28) 4 (1.80) 24 (7.52) 33 (3.55)
Observations, postoperative or symptom based 4 (5.33) 46 (14.70) 26 (11.70) 44 (13.80) 120 (12.90)
Neurological including convulsions 1 (1.33) 24 (7.67) 39 (17.60) 77 (24.10) 141 (15.20)
Malformations 30 (40.00) 46 (14.70) 17 (7.66) 4 (1.25) 97 (10.40)
Respiratory 20 (26.70) 91 (29.10) 69 (31.10) 72 (22.60) 252 (27.10)
Unknown 0 (0) 0 (0) 1 (0.45) 0 (0) 1 (0.11)

IQR = inter quartile range. Diagnostic groups based on the reason for PICU admission.

Survival and sex after single and repeated admissions to PICU

The SMR for all patients admitted to the PICU during the study period was 49.8 (95%CI 44.8–55.4). There was a statistically significant difference in survival for patients with a single admission and patients with subsequent repeated admissions to PICU (p<0.0001), Fig 2. No significant difference was found in survival between boys and girls neither with a single admission (p = 0.57), nor with repeated admissions to PICU (p = 0.22), Fig 2. The number of patients at follow-up years 0 to 12 for the entire study cohort is presented as supplementary material (S3 Table). After 4 years, the survival rate was 0.942 and 0.936 for boys and girls with a single admission to PICU, respectively. For patients with repeated admissions to PICU the four-year survival rate was 0.847 for boys and 0.822 for girls, respectively. Of all deaths (n = 444) in the study cohort, 30.0% (n = 133) died in PICU. PICU death rate for the entire study cohort was 2.84%, and none-PICU death rate was 6.64%. Death rate during the first year after PICU discharge for the entire study cohort was 4.25% (n = 199).

Fig 2. Survival rates from the first admission to the PICU.

Fig 2

The figure shows a comparison of the survival rate with time from the first admission to the PICU after single and repeated admissions respectively. Solid lines = Data from patients with a single admission. Dotted lines: Data from patients with repeated admissions. Blue lines: Data from boys. Red lines: Data from girls.

SMR and follow-up time after single and repeated admissions to PICU

SMRs at different time periods after PICU admission are shown in Fig 3. The SMRs for the follow up period from PICU admission (= 0 years) until the end of the observation period, i.e., up to 12.5 years, for the PICU patient population with single and repeated admissions was 35.2 (95% CI: 30.5–40.6) and 108.0 (95% CI: 91.9–126.9), respectively. At the 1-year follow up, i.e., one year after PICU admission to the end of the observation period, the SMRs had decreased to 18.2 (95% CI:13.7–24.0) for single and 65.5 (95% CI: 50.9–70.2) for repeated admissions, respectively. The SMRs were 11.0 (95% CI: 7.0–17.6) and 33.9 (95% CI: 23.9–48.0) at the 4-year follow-up, i.e., four years after PICU admission to the end of the observation period, for single and repeated admissions respectively. Of all deaths (n = 444) in the study cohort, 30.9% (n = 137) died in PICU. Subsequent mortality during the first year after PICU discharge was 46.0% (n = 204).

Fig 3. SMR at different time periods after PICU admission to the end of the observation period.

Fig 3

The figure shows a comparison of SMR from patients with a single admission (Closed symbols) and repeated admissions (Open symbols). SMR expresses the mortality risk, as compared to the general population of the same age and sex. The 95% confidence intervals are given by the error bars. Statistical significances are indicated by non-overlapping confidence intervals. EOP = End of Observation Period.

SMR, age and risk stratification groups

In patients with a single admission there were 3,400 children with a PDR of 0–10%. In this PDR group the SMR of 22.0 was outside the lower 99.8% confidence limit of SMR for the entire study group. In all other PDR groups SMR was outside the upper 99.8% confidence limit. Patients aged 0–28 d with a single admission (n = 779), had a SMR of 17.0 which was outside the lower 99.8% confidence limit. Children aged >1–4 years with a single admission (n = 728) had a SMR of 74.7 which was outside the upper 99.8% confidence limit, Fig 4A.

Fig 4. Funnel plots showing SMR for different age and risk stratification groups.

Fig 4

The presented data are from the first admission to the PICU. A: Single admission to PICU. B: Repeated admissions to PICU. The 95 and 99.8% confidence intervals of SMR of the entire study population, in relation to number of cases, are given by the solid and dotted lines, respectively.

For patients with repeated admissions to PICU, the PDR group 0–10% (n = 798) had a SMR of 100 at their first admission. PDR groups 10–25% and 25–50% were outside the upper 95% confidence limits. PDR group > 50% was within the 95% confidence limits of SMR for the study group. Neonatal children aged 0–28 d, with repeated admissions (n = 229) had a SMR of 51.4 which was outside the lower 99.8% confidence limit. Children aged >1–4 years had a SMR of 325 which was outside the upper 99.8% confidence limit, Fig 4B.

SMR and diagnostic groups

The SMR for the various PICU admission diagnosis, compared to the general population, both for patients with a single admission and at the first admission in patients with repeated PICU admissions is illustrated in Fig 5. In all diagnostic groups, with exception for the Cardiovascular/Circulatory group, the SMR was higher in patients with repeated admissions at their first admission as compared to patients with a single admission.

Fig 5. Bar graph showing SMR for different PICU admission diagnosis.

Fig 5

The presented data are from the first admission to the PICU. The SMRs are derived from the general population.

In patients with a single admission the SMR showed a 191-fold increased mortality rate in patients admitted due to cardiovascular/circulatory diagnosis. The second highest SMR was found in the group of patients with oncology/hematology diagnosis (SMR 179). In the groups of patients with diagnosis of Malformation, Trauma/Poison and Certain perinatal conditions the SMR showed the lowest mortality rates (17.9, 18.6 and 20.5), respectively.

The SMR showed a 358-fold increased mortality rate in patients admitted due to oncology/hematology diagnoses, at the first admission, in patients with repeated PICU admissions. The second highest SMR (192) was found in the group admitted due to neurology (including convulsions) diagnosis. In the groups of patients with Trauma/Poison and Malformation as causes for admission the SMR showed the lowest mortality rate (36.1 and 57.7), respectively.

Discussion

To our knowledge this is the first study which has compared the mortality of a PICU cohort, using data on the severity of illness affecting the study cohort, to the mortality of the general population of the same age and sex. The study has an extended longitudinal follow-up, of at least four but up to twelve years, which is well beyond the typical duration of study follow-up in intensive care.

There was a significant mortality during the first year after admission to PICU in the entire patient population as reflected by the decrease in survival rate seen in Fig 2. Nearly 50% of all deaths occurred during the first year after PICU discharge, indicating a clinically significant delayed mortality. During the following years only a minor decrease in survival was seen in patients with a single admission. In contrast, there was a continuing decrease in survival during the entire observation period for patients with repeated admissions to PICU.

No statistically significant difference in survival was found between boys or girls, irrespective if they had a single admission to PICU, or if they were repeatedly admitted, Fig 2. These results are unlike reports from previous studies, where survival analysis have shown an advantage for boys [2527].

The increased mortality rate found in the present study is much higher than in previous reports from both Finland and Sweden where corresponding risks compared to the general population have been reported to be six-fold and 20-fold greater, respectively [17, 18]. In the present study PICU patients were separated into single and repeated admissions which partly can explain this difference. For patients with a single admission, the SMR showed an 11-fold increased mortality rate compared to the general population four years after PICU admission Fig 3, which is still higher than in the Finnish study, but could be explained by a high rate of postoperative admissions with length of stay in PICU less than 24 hours in that report [18].

The highest SMR was found in the age group > 1–4 years, and the lowest was found in the neonatal group, Fig 4. This was regardless of children being admitted one or repeated times to PICU. Neonatal children in this study may have lower than expected SMRs because the children were not managed in a NICU and were no more premature than 36 weeks. Even though they still had elevated SMR compared to the general population, this may have inflated their survivability compared to the remainder of the PICU population, causing the SMR to be below the 99.8% confidence limit. Additionally, a neonate <28 days old with multiple PICU admissions nearly by definition survived the neonatal period.

Children >1–4 years with repeated admissions had a SMR which showed a more than 300-fold increased mortality rate, compared with the general population, at their first admission. Oncology/hematology and neurologic diagnosis at admission accounted for nearly 30% of PICU admissions in this patient group which might be a contributing factor to the high mortality risk seen in this age group.

The lowest mortality rate was found in risk stratification group 0–10% with a single admission to PICU. Even though the mortality rate for this risk stratification group was lower than the confidence limit in the funnel plot, the group still had a 20-fold increased mortality risk compared to the general population. All other risk stratification groups with a single admission to PICU appeared outside the upper confidence limit, indicating a higher mortality rate compared to the entire study population with single admissions, Fig 4A.

The considerable increased mortality risk seen in this study also included risk stratification group 0–10%. PICU-patients with an acute complication added to complex chronic illness, which is known to account for a considerable part of admissions to PICU [11, 1416], but not necessarily captured in the PIM-score, could be an explanation.

Oncology/hematology diagnosis had the highest increased mortality rates compared to the general population in the group of patients with repeated admissions to PICU, Fig 5. High increased mortality rates, compared to the general population, in patients with repeated admissions to PICU was also seen in other medical diagnostic groups such as neurology, nephrology, and cardiovascular diseases. As shown in other reports the injury diagnostic group carried a low mortality, compared to the general population [17, 18]. It is expected that underlying complex chronic disease is less frequent in this diagnostic group.

A strength of this study is the linking of PICU data to a national registry to evaluate long-term survival.

Furthermore, consecutive patients were included, they were categorized by diagnoses set by the treating physician in the PICU and not by the researchers involved. The main limitation of the study is that we lack information on the prevalence of complex chronic illness. Our ambition is to collect information on the presence of complex chronic conditions in a follow-up study. Data on long-term morbidity and quality of life, which are important outcome factors after critical illness and pediatric intensive care, were also not possible to obtain. To illuminate questions around chronic illness patients were stratified into single versus repeated admissions. Multiple PICU admissions likely functions as a surrogate marker for chronic illness, accounting for the increase mortality risk in these patients. This is further supported by the lower number of "repeat" patients with trauma/poisoning diagnoses. Third, although our study contains data over twelve years, a limitation is that data originates from a single center, and thereby limiting generalizability.

Finally, we were not able to remove the study group from the matched general population, since we were not able to separate this group in the national registers. If any effect at all, this means that the calculated SMRs could be expected to be even higher if the study group had been excluded from the matched general population.

Conclusion

Compared to the age and sex matched Swedish population, the SMR for all patients admitted to the PICU during the study period was nearly 50. SMRs in general were three times higher for patients with repeated admissions to PICU compared to single admitted patients. There was significant excess mortality over time in PICU survivors. SMRs were greatly elevated up to four years after PICU admission, declining from over 100 to 33 for patients with repeated PICU admissions, and from 35 to 11 for patients with a single PICU admission.

Supporting information

S1 Table. Complete dataset on the entire study population.

Anonymized.

(PDF)

S2 Table. Number of repeated admissions.

The hierarchical nature of patients with repeated admissions to PICU.

(PDF)

S3 Table. Patients at risk.

The number of patients at follow-up years 0 to 12 for the entire study cohort.

(PDF)

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

Tova Hannegård Hamrin (THH) reported grants from Her Royal Highness Crown Princess Lovisa Foundation: reference id 2021-00670. https://www.kronprinsessanlovisa.se/ The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Namachivayam P, Shann F, Shekerdemian L, Taylor A, van Sloten I, Delzoppo C, et al. Three decades of pediatric intensive care: Who was admitted, what happened in intensive care, and what happened afterward. Pediatr Crit Care Med. 2010; 11(5):549–555. doi: 10.1097/PCC.0b013e3181ce7427 [DOI] [PubMed] [Google Scholar]
  • 2.Pinto NP, Rhinesmith EW, Kim TY, Ladner PH, Pollack MM. Long-term function after pediatric critical illness: Results from the survivor outcomes study. Pediatr Crit Care Med. 2017; 18(3):e122–e130. doi: 10.1097/PCC.0000000000001070 [DOI] [PubMed] [Google Scholar]
  • 3.Namachivayam SP, Butt W. Outcomes after pediatric critical illness: important to be accurate. Pediatr Critil Care Med. 2016; 17(6):576–577. doi: 10.1097/PCC.0000000000000741 [DOI] [PubMed] [Google Scholar]
  • 4.Pearson G, Shann F, Barry P, Vyas J, Thomas D, Powell C, et al. Should paediatric intensive care be centralized? Trent versus Victoria. Lancet. 1997; 349(9060): 1213–1217. doi: 10.1016/S0140-6736(96)12396-5 [DOI] [PubMed] [Google Scholar]
  • 5.Shann F, Pearson G. Paediatric intensive care—specialisation reduces mortality. Anaesthesia. 1999;54(8):809–810. doi: 10.1046/j.1365-2044.1999.1039a.x [DOI] [PubMed] [Google Scholar]
  • 6.Pollack MM, Alexander SR, Clarke N, Ruttimann UE, Tesselaar HM, Bachulis AC. Improved outcomes from tertiary center pediatric intensive care: a statewide comparison of tertiary and nontertiary care facilities. Crit Care Med. 1991; 19(2): 150–159. doi: 10.1097/00003246-199102000-00007 [DOI] [PubMed] [Google Scholar]
  • 7.Gemke RJ. Centralization of paediatric intensive care to improve outcome. Lancet. 1997; 349(9060): 1187–1188. doi: 10.1016/s0140-6736(05)62407-5 [DOI] [PubMed] [Google Scholar]
  • 8.Ramnarayan P, Thiru K, Parslow RC, Harrison DA, Draper ES, Rowan KM. Effect of specialist retrieval teams on outcomes in children admitted to paediatric intensive care units in England and Wales: a retrospective cohort study. Lancet 2010; 376(9742): 698–704. doi: 10.1016/S0140-6736(10)61113-0 [DOI] [PubMed] [Google Scholar]
  • 9.Hannegård Hamrin T, Radell PJ, Fläring U, Berner J, Eksborg S. Short- and long-term outcome in critically ill children after acute interhospital transport to a PICU in Sweden. Pediatr Crit Care Med. 2020;21(7):e414–e425. doi: 10.1097/PCC.0000000000002319 [DOI] [PubMed] [Google Scholar]
  • 10.Volakli EA, Sdougka M, Drossou-Agakidou V, Emporiadou M, Reizoglou M, Giala M. Short-term and long-term mortality following pediatric intensive care. Pediatr Int. 2012;54(2): 248–255. doi: 10.1111/j.1442-200X.2011.03545.x [DOI] [PubMed] [Google Scholar]
  • 11.Kalzén H, Larsson B, Eksborg S, Lindberg L, Edberg KE, Frostell C. Survival after PICU admission: The impact of multiple admissions and complex chronic conditions. PLoS One. 2018;13(4):e0193294. doi: 10.1371/journal.pone.0193294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Jones S, Rantell K, Stevens K, Colwell B, Ratcliffe LR, Holland P, et al. United Kingdom Pediatric Intensive Care Outcome Study Group. Outcome at 6 months after admission for pediatric intensive care: A report of a national study of pediatric intensive care units in the United Kingdom. Pediatrics. 2006; 118(5):2101–2108. doi: 10.1542/peds.2006-1455 [DOI] [PubMed] [Google Scholar]
  • 13.Gemke RJ, Bonsel GJ, van Vught AJ. Long-term survival and state of health after paediatric intensive care. Arch Dis Child. 1995; 73(3):196–201. doi: 10.1136/adc.73.3.196 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Pollack MM, Holubkov R, Funai T, Berger JT, Clark AE, Meert K, et al. Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Simultaneous prediction of new morbidity, mortality, and survival without new morbidity from pediatric intensive care: A new paradigm for outcomes assessment. Crit Care Med. 2015; 43(8):1699–1709. doi: 10.1097/CCM.0000000000001081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Feudtner C, Hexem KR, Shabbout M, Feinstein JA, Sochalski J, Silber JH. Prediction of pediatric death in the year after hospitalization: a population-level retrospective cohort study. J Palliat Med. 2009; 12(2):160–169. doi: 10.1089/jpm.2008.0206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Namachivayam SP, Alexander J, Slater A, Millar J, Erickson S, Tibballs J, et al. Five-year survival of children with chronic critical illness in Australia and New Zealand. Crit Care Med. 2015; 43 (9):1978–1985. doi: 10.1097/CCM.0000000000001076 [DOI] [PubMed] [Google Scholar]
  • 17.Gullberg N, Kalzén H, Luhr O, Göthberg S, Winsö O, Markström A, et al. Scandinavian Critical Care Trials Group: Immediate and 5-year cumulative outcome after paediatric intensive care in Sweden. Acta Anaesthesiol Scand. 2008; 52(8):1086–1095. doi: 10.1111/j.1399-6576.2008.01711.x [DOI] [PubMed] [Google Scholar]
  • 18.Kyösti E, Liisanantti JH, Peltoniemi O, Ohtonen P, Rautiainen P, Kataja J, et al. Five-year survival and causes of death in children after intensive care-a national registry study. Pediatr Crit Care Med. 2018;19(3):e145–e151. doi: 10.1097/PCC.0000000000001424 [DOI] [PubMed] [Google Scholar]
  • 19.Slater A, Shann F, Pearson G. Paediatric Index of Mortality (PIM) Study Group: PIM2: A revised version of the Paediatric Index of Mortality. Intensive Care Med. 2003; 29(2):278–285. doi: 10.1007/s00134-002-1601-2 [DOI] [PubMed] [Google Scholar]
  • 20.Shann F, Pearson G, Slater A, Wilkinson K. Paediatric Index of Mortality (PIM): A mortality prediction model for children in intensive care. Intensive Care Med. 1997; 23(2):201–207. doi: 10.1007/s001340050317 [DOI] [PubMed] [Google Scholar]
  • 21.Statistics Sweden (Statistiska Centralbyrån, Statistikmyndigheten SCB) [Cited 2022 February 23] https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101I/Dodstal/
  • 22.Cook DA, Duke G, Hart GK, Pilcher D, Mullany D. Review of the application of risk-adjusted charts to analyse mortality outcomes in critical care. Crit Care Resusc. 2008; 10(3):239–251 [PubMed] [Google Scholar]
  • 23.Woolson RF. Rank-tests and a one-sample log-rank test for comparing observed survival-data to a standard population. Biometrics. 1981;37: 687–696. [Google Scholar]
  • 24.Finkelstein DM, Muzikansky A, Schoenfeld DA. Comparing survival of a sample to that of a standard population. J Natl Cancer Inst. 2003;95(19): 1434–1439. doi: 10.1093/jnci/djg052 [DOI] [PubMed] [Google Scholar]
  • 25.Johansson Frigyesi E, Andersson P, Frigyesi A. Boys have better short-term and long-term survival rates after intensive care admissions than girls. Acta Paediatr. 2017; 106(12):1973–1978. doi: 10.1111/apa.14044 [DOI] [PubMed] [Google Scholar]
  • 26.Epstein D, Wong CF, Khemani RG, Moromisato DY, Waters K, Kipke MD, et al. Race/Ethnicity is not associated with mortality in the PICU. Pediatrics. 2011; 127(3):e588–e597. doi: 10.1542/peds.2010-0394 [DOI] [PubMed] [Google Scholar]
  • 27.Esteban E, Bujaldon E, Esparza M, Jordan I, Esteban ME. Sex differences in children with severe health conditions: Causes of admission and mortality in a Pediatric Intensive Care Unit. Am J Hum Biol. 2015; 27(5): 613–619. doi: 10.1002/ajhb.22709 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Brenda M Morrow

18 Apr 2022

PONE-D-22-06716Risks for death after admission to pedaitric intensive care (PICU) - a comparison with the general populationPLOS ONE

Dear Dr. Hannegård Hamrin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 02 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Brenda M. Morrow, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. Please note that in order to use the direct billing option the corresponding author must be affiliated with the chosen institute. Please either amend your manuscript to change the affiliation or corresponding author, or email us at plosone@plos.org with a request to remove this option.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have utilised a large population based dataset to compare mortality in PICU patients in PICU or after discharge and have compared this, suing relative measure, to the general population of children. Given that children are admitted to PICU with life-threatening medical or surgical condition it is unsurprising that their SMR is markedly higher that the general population. I am also unclear how valuable using relative measures of risk alone are in this situation - in fact could cause great concern amongst parents. I think further re-analyses and clarification of the importance of these findings i.e "so what' are important before this paper is suitable for publication.

Major concerns

1. please present absolute risks as well as relative risks throughout the manuscript

2. please clearly articulate the 'so what' of these analyses

3. Is the diagnostic group based on reason for admission to PICU or underlying health conditions? Most children admitted to PICU have underlying complex medical condition so understanding this groups is very important when thinking through the implications of this study.

4. I would ask that the authors present the data for within PICU and after PICU discharge mortality see this paper https://adc.bmj.com/content/103/6/540. Understanding the risk after discharge is really important in terms of needs for palliative care services and parental expectations

5. What about children with multiple diagnoses, they often have higher risk of mortality?

6. I am unclear how the hierarchical nature of these data have been accounted for in these analyses - ie. children with multiple admissions?

7. Please present the numbers of children where life-sustaining treatment was withdrawn within ICU

8. all these comments relate to being able to identify (prospectively) which children may be at higher risk of death- doing this retrospectively once they have had more than one PICU admission is not necessarily that useful

Minor points

1. two decimal places are adequate in tables

2. this sentence is incorrect "Subsequent mortality during the first year

176 after PICU discharge was 46.0% (n=204)" and should be corrected

Reviewer #2: Thank you for the opportunity to review this paper, which compared the mortality of PICU-admitted children to those of the matched general Swedish population.

The comparison was further stratified into various categories: age, risk factor (via PIM2), and diagnosis. Importantly, splitting patients according to whether they had only a single PICU admission or multiple ones was appropriate because the authors’ premise about multiple PICU admissions serving as a proxy for chronic illness/conditions is a sound one.

Main comment:

My biggest issue is the lack of granularity in the data provided in the submission. Having the raw numbers of what went into the SMR calculations would be helpful; at the very least – the observed deaths of the PICU patients at the follow-up times, in the binned categories, etc). Would it be possible to provide this as Supplementary Material? The SMRs shown in Figures 3-5 can only be eye-balled and cannot be reproduced from the data provided in the submission. This is why I answered “No” to Question 3 (regarding data underlying findings in the manuscript).

These questions/comments are to help clarify details of computations and Figures:

a) Figure 2: Assuming that the study year was 2020, the number of total patients (needed in the denominator) after year 4 is steadily decreasing – e.g. all admissions (years 2008-2016) are eligible for Time<4 years, but only those admitted in 2008 are available at Time=12 years (after admission). It might be helpful to annotate in the Figure (or provide in a supplementary table) the number of patients at each time point (years after admission) that the survival rate is being plotted.

b) Figure 3 and lines 169-171 either show or mention SMR at “PICU admission” – this may be a misunderstanding on my part, but how do you get a non-zero SMR (i.e. non-zero observed deaths) at time of admission? For this, are you counting the deaths that occurred in the PICU at some later time than admission?

c) On page 14, line 191 states “All PDR groups were within the 95% CI limits of SMR …” – this is for repeated admissions; however in Figure 4B, the SMRs for 2 PDR groups (10-25%, 25-50%) look just a little outside the limits.

Other (minor) comments:

i) Full title in the submission (not manuscript) – “pedaitric” should be “pediatric”

ii) Lines 227-228 (Discussion section) – Figure 2 (the survival rate) is a stronger support for this statement than the 1-year SMR.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Professor Lorna Fraser

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Oct 7;17(10):e0265792. doi: 10.1371/journal.pone.0265792.r002

Author response to Decision Letter 0


11 May 2022

Responses to Reviewers' Comments to Author,

Thank-you to both Reviewers for your constructive and thoughtful comments and suggestions. We are grateful for the opportunity to revise our article and agree that the manuscript can be and has been much improved by changes according to your suggestions.

Below, are our responses to your suggestions and comments.

Reviewer #1: The authors have utilised a large population based dataset to compare mortality in PICU patients in PICU or after discharge and have compared this, suing relative measure, to the general population of children. Given that children are admitted to PICU with life-threatening medical or surgical condition it is unsurprising that their SMR is markedly higher that the general population. I am also unclear how valuable using relative measures of risk alone are in this situation - in fact could cause great concern amongst parents. I think further re-analyses and clarification of the importance of these findings i.e "so what' are important before this paper is suitable for publication.

Major concerns

1. please present absolute risks as well as relative risks throughout the manuscript

Reply: Thank you for your comment. In this study we have evaluated and reported SMR (standardized mortality ratio) according to the original article by reference 24 in the list of references: Finkelstein DM, Muzikansky A, Schoenfeld DA. Comparing survival of a sample to that of a standard population. J Natl Cancer Inst. 2003;95: 1434-1439.

When comparing survival of a study cohort with an age and sex matched general population, we think that using the method as described in this reference article is to be preferred.

The use of SMR and its Confidence intervals as a statistical method is further described by

Liddell FD: Simple exact analysis of the standardised mortality ratio. J Epidemiol Community Health.

1984; 38:85–88.

2. please clearly articulate the 'so what' of these analyses

Reply: Thank you for this valuable comment. We agree with the reviewer and think that the conclusion section could be improved and have therefore made a revision.

3. Is the diagnostic group based on reason for admission to PICU or underlying health conditions? Most children admitted to PICU have underlying complex medical condition so understanding this groups is very important when thinking through the implications of this study.

Reply: Thank you for your question. The diagnostic groups are based on reason for admission to PICU. We have further clarified this in the Material and Methods section page 7, Results section page 9 and in the footnotes of Tables 1-3.

4. I would ask that the authors present the data for within PICU and after PICU discharge mortality see this paper https://adc.bmj.com/content/103/6/540. Understanding the risk after discharge is really important in terms of needs for palliative care services and parental expectations

Reply: Thank you for this suggestion. We have now included results on death rates for the entire study population separated in: PICU death rate, non PICU death rate and death rate during the first year after PICU discharge in the Results section, page 13.

5. What about children with multiple diagnoses, they often have higher risk of mortality?

Reply: Thank you for this comment; we agree with the reviewer that the absence of data on chronic comorbidities is a weakness. To illuminate questions around children with chronic complex illness, patients were stratified into single versus repeated admissions. Multiple PICU admissions likely functions as a surrogate marker for chronic illness, accounting for the increased mortality risk in these patients. The findings are discussed and the lack of data on chronic comorbidities for the entire study cohort are acknowledged in the list of study limitations.

6. I am unclear how the hierarchical nature of these data have been accounted for in these analyses - ie. children with multiple admissions?

Reply: Thank you for your suggestion to clarify this, a table has been included as supplementary material (Suppl. Table S2).

7. Please present the numbers of children where life-sustaining treatment was withdrawn within ICU

Reply: Thank you for your comment. In this study we have not investigated any causes of death, and therefore we are unable to present the numbers of children where life-sustaining treatment was withdrawn within PICU.

8. all these comments relate to being able to identify (prospectively) which children may be at higher risk of death- doing this retrospectively once they have had more than one PICU admission is not necessarily that useful

Reply: Thank you for your comment. We believe that there might be a small misunderstanding due to lack of clarity in our manuscript and we are grateful for the opportunity to make clarifications.

The aim of the present study was to quantify excess mortality over time in children post admission to a PICU, compared with a control population of same age and sex, ie. the matched general Swedish population. Thus, our aim in this study was not to prospectively identify which children may be at higher risk of death.

Minor points

1. two decimal places are adequate in tables

Reply: Thank you for your suggestion about the number of decimals. We agree with the reviewer and have changed accordingly in the manuscript.

2. this sentence is incorrect "Subsequent mortality during the first year

176 after PICU discharge was 46.0% (n=204)" and should be corrected

Reply: Thank you for this comment; we have changed the text according to the suggestion.

Reviewer #2: Thank you for the opportunity to review this paper, which compared the mortality of PICU-admitted children to those of the matched general Swedish population.

The comparison was further stratified into various categories: age, risk factor (via PIM2), and diagnosis. Importantly, splitting patients according to whether they had only a single PICU admission or multiple ones was appropriate because the authors’ premise about multiple PICU admissions serving as a proxy for chronic illness/conditions is a sound one.

Main comment:

My biggest issue is the lack of granularity in the data provided in the submission. Having the raw numbers of what went into the SMR calculations would be helpful; at the very least – the observed deaths of the PICU patients at the follow-up times, in the binned categories, etc). Would it be possible to provide this as Supplementary Material? The SMRs shown in Figures 3-5 can only be eye-balled and cannot be reproduced from the data provided in the submission. This is why I answered “No” to Question 3 (regarding data underlying findings in the manuscript).

Reply: We thank the reviewer for pointing out this important weakness. We are grateful for the opportunity to make clarifications and have now included data on admission year, follow up time, age at admission, sex, outcome (deceased/alive), PDR, and PICU admission diagnosis for the entire study population in Supplementary material as Suppl. Table S1.

These questions/comments are to help clarify details of computations and Figures:

a) Figure 2: Assuming that the study year was 2020, the number of total patients (needed in the denominator) after year 4 is steadily decreasing – e.g. all admissions (years 2008-2016) are eligible for Time<4 years, but only those admitted in 2008 are available at Time=12 years (after admission). It might be helpful to annotate in the Figure (or provide in a supplementary table) the number of patients at each time point (years after admission) that the survival rate is being plotted.

Reply: Thank you for this valuable comment. We agree that the number of patients at each time point for follow-up should be clarified and have now included a supplementary table (Suppl. Table S3) to give an overview of the number of patients at follow-up years 0 to 12 for the entire study cohort. Patients are presented as single/repeated admissions and female/male admissions.

b) Figure 3 and lines 169-171 either show or mention SMR at “PICU admission” – this may be a misunderstanding on my part, but how do you get a non-zero SMR (i.e. non-zero observed deaths) at time of admission? For this, are you counting the deaths that occurred in the PICU at some later time than admission?

Reply: We appreciate this comment, to clarify we have made changes in the manuscript accordingly, page 14, and have rewritten the text on the x-axis in Figure 3.

c) On page 14, line 191 states “All PDR groups were within the 95% CI limits of SMR …” – this is for repeated admissions; however in Figure 4B, the SMRs for 2 PDR groups (10-25%, 25-50%) look just a little outside the limits.

Reply: We thank the reviewer for pointing this out to us. We have corrected the text accordingly, page 14-15.

Other (minor) comments:

i) Full title in the submission (not manuscript) – “pedaitric” should be “pediatric”

Reply: Thank you. We have corrected the text accordingly.

ii) Lines 227-228 (Discussion section) – Figure 2 (the survival rate) is a stronger support for this statement than the 1-year SMR.

Reply: We agree and have changed the text according to the suggestion, page 16.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Thomas Tischer

13 Jul 2022

PONE-D-22-06716R1Risks for death after admission to pediatric intensive care (PICU) - a comparison with the general populationPLOS ONE

Dear Dr. Hannegård Hamrin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewer ask for some additional clarifications regarding Figure 3. Could you please revise the manuscript to address these concerns?

Please submit your revised manuscript by Aug 26 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Thomas Tischer

Staff Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thank you for providing the supplementary material. The responses, along with the additional tables in the supplements, addressed most of my previous concerns.

I have a remaining comment/question regarding Figure 3. In my previous review, I had asked about the non-zero SMR at year=0 (time of PICU admission). The response did not really clear up my original question.

In Figure 3, there is a certain "binning" taking place for the number of years on the horizontal axis, i.e. data are plotted only for discrete years 0, 1, 2, 3, 4, and 5 after PICU admission. When you plot the SMR for say year=0, are you counting the observed deaths up to, but strictly less than, 1 year from PICU admission? Likewise, does the SMR for year=1 reflect observed deaths that occurred at least 1 year, but strictly less than 2 years, after PICU admission?

This revised statement -- "The SMRs, during the total follow-up time for the entire PICU patient population with single and repeated admissions was 35.2% ... and 108.0 ...." (lines 176-179, page 14) -- where the stated numbers correspond to the year=0 point on the horizontal axis, still does not track with my understanding of what Figure 3 is supposed to be showing. How does "total follow-up time" track with year=0?

Figure 3, especially the number corresponding to year=0 for repeated admissions, is referenced in the Discussion section, so please make sure to explain clearly/thoroughly what year=0 (after PICU admission) really mean.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Oct 7;17(10):e0265792. doi: 10.1371/journal.pone.0265792.r004

Author response to Decision Letter 1


23 Aug 2022

Thank you for the opportunity to revise our manuscript.

The concern raised by reviewer #2 was that clarifications were needed regarding what Figure 3 is supposed to be showing, especially whether data are plotted only for discrete years and what year=0 after PICU admission means. Significant effort has therefore been put into making a focused effort to improve Figure 3 and its Figure legend. Clarifications have been made accordingly in the result and discussion sections of the manuscript as can be seen in the accompanying “Responses to Reviewer”.

Attachment

Submitted filename: Responses to Reviewers.docx

Decision Letter 2

Robert Jeenchen Chen

8 Sep 2022

Risks for death after admission to pediatric intensive care (PICU) - a comparison with the general population

PONE-D-22-06716R2

Dear Dr. Hannegård Hamrin,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thank you for making the clarification about Figure 3.

Reviewer #3: No additional comments from me as I think my previous comments were already addressed in the previous version.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

**********

Acceptance letter

Robert Jeenchen Chen

27 Sep 2022

PONE-D-22-06716R2

Risks for death after admission to pediatric intensive care (PICU) - a comparison with the general population

Dear Dr. Hannegård Hamrin:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Robert Jeenchen Chen

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Complete dataset on the entire study population.

    Anonymized.

    (PDF)

    S2 Table. Number of repeated admissions.

    The hierarchical nature of patients with repeated admissions to PICU.

    (PDF)

    S3 Table. Patients at risk.

    The number of patients at follow-up years 0 to 12 for the entire study cohort.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Responses to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES